

INTEGRATED BIOPHARMA INC
Form 10-Q
May 17, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2011

OR

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File Number 001-31668

INTEGRATED BIOPHARMA, INC.
(Exact name of registrant, as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

22-2407475
(I.R.S. Employer
Identification No.)

225 Long Ave., Hillside, New Jersey
(Address of principal executive offices)

07205
(Zip Code)

(888) 319-6962
(Registrant's telephone number, including Area Code)

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

FORM 10-Q QUARTERLY REPORT
For the Nine Months Ended March 31, 2011
INDEX

	Page
Part I. Financial Information	
Item 1.	
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended March 31, 2011 and 2010 (unaudited)	2
Condensed Consolidated Balance Sheets as of March 31, 2011 and June 30, 2010 (unaudited)	3
Condensed Consolidated Statement of Changes in Stockholders' Deficiencies for the Nine Months Ended March 31, 2011 (unaudited)	4
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2011 and 2010 (unaudited)	5
Notes to Condensed Consolidated Statements	6
Item 2.	
Management's Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	
Quantitative and Qualitative Disclosures about Market Risk	26
Item 4.	
Controls and Procedures	26
Part II. Other Information	
Item 1.	
Legal Proceedings	27
Item 1A.	
Risk Factors	27
Item 2.	
Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 3.	
Defaults Upon Senior Securities	27
Item 5.	
Other Information	27
Item 6.	
Exhibits	27
	Other
Signatures	28

Disclosure Regarding Forward-Looking Statements

Certain statements in the Quarterly Report on Form 10-Q may constitute “forward-looking” statements as defined in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Act of 1934, as amended (the “Exchange Act”), the Private Securities Litigation Reform Act of 1995 (the “PSLRA”) or in releases made by the Securities and Exchange Commission, all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Integrated BioPharma, Inc. (the “Company”) or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements that are not historical fact are forward-looking statements. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as the words, “plan”, “believe”, “expect”, “anticipate”, “intend”, “estimate”, “project”, “may”, “will”, “would”, “could”, “should”, “seeks”, or “scheduled to”, or other similar terms or the negative of these terms or other variations of these terms or comparable language, or by discussion of strategy or intentions. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the “safe harbor” provisions of such laws. The Company cautions investors that any forward-looking statements made by the Company are not guarantees or indicative of future performance. Important assumptions and other important factors that could cause actual results to differ materially from those forward-looking statements with respect to the Company, include, but are not limited to, the risks and uncertainties affecting its businesses described in Items 1 and 1A of the Company’s Annual Report filed on Form 10-K for the year ended June 30, 2010 and in registration statements and other securities filings by the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any of the forward-looking statements and are subject to change due inherent risks and uncertainties. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made only as of the date hereof and the Company does not have or undertake any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

ITEM 1. FINANCIAL STATEMENTS

2

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF MARCH 31, 2011 AND JUNE 30, 2010 AND FOR THE
THREE AND NINE MONTHS ENDED MARCH 31, 2011 AND 2010
(in thousands, except share and per share amounts)

Note 1. Principles of Consolidation and Basis of Presentation

The accompanying condensed financial statements for the interim periods are unaudited and include the accounts of the Company. The interim condensed consolidated financial statements have been prepared in conformity with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and therefore do not include information or footnotes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America. However, all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented have been included. These condensed financial statements should be read in conjunction with the financial statements and notes thereto, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2010 (“10-K”), as filed with the SEC. The June 30, 2010 balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The results of operations for the three and nine months ended March 31, 2011, are not necessarily indicative of the results for the full fiscal year ending June 30, 2011 or for any other period.

Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors.

The Company’s nutraceutical business includes: InB:Manhattan Drug Company, Inc. (“Manhattan Drug”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and The Vitamin Factory, which sells private label Manhattan Drug products, as well as our AgroLabs, Inc. (“AgroLabs”) products, through the Internet.

The Company also distributes fine natural chemicals through its wholly-owned subsidiary IHT Health Products, Inc. and is a distributor of certain raw materials for DSM Nutritional Products, Inc.

These condensed consolidated financial statements reflect the classification as discontinued operations of our branded proprietary Nutraceutical business which is operated by AgroLabs, a wholly owned subsidiary of the Company, which distributes for sale through major mass market, grocery, drug and vitamin retailers, healthful nutritional products under the following brands: Naturally Noni, Naturally Pomegranate, Naturally Aloe, Aloe Pure, Naturally Thai Mangosteen, Peaceful Sleep, Green Envy, 1st Choice Multi-Vitamin, ACAI Extra, ACAI Immune, ACAI Cleanse, and other products which are being introduced into the market. These are referred to as our branded proprietary Nutraceutical business and/or products. (see Note 3. – Discontinued Operations).

Reclassifications. Certain reclassifications have been made to the amounts reported for the prior year to conform with the current year presentation.

Principles of Consolidation. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, and any majority-owned investment. Intercompany transactions and accounts are eliminated in consolidation.

Estimates. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The most significant estimates include:

6

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF MARCH 31, 2011 AND JUNE 30, 2010 AND FOR THE
THREE AND NINE MONTHS ENDED MARCH 31, 2011 AND 2010
(in thousands, except share and per share amounts)

- sales returns and allowances;
- trade marketing and merchandising;
- allowance for doubtful accounts;
 - inventory valuation;
- valuation and recoverability of long-lived and intangible assets, including the values assigned to acquired intangible assets; and
 - income taxes and valuation allowance on deferred income taxes.

On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Nothing has come to our attention which would cause a change in these estimates.

Investment in iBio, Inc. The Company accounts for its investment in iBio on the cost basis as it retained approximately 6% of its interest in iBio at the time of the spin-off of this subsidiary in August 2008. The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be an impairment of the investment.

Revenue Recognition. For product sales, the Company recognizes revenue when the product's title and risk of loss transfers to the customer. The Company believes this revenue recognition practice is appropriate because the Company's sales policies meet the following four criteria: (i) persuasive evidence that an arrangement exists, (ii) delivery has occurred, (iii) the seller's price to the buyer is fixed and determinable and (iv) collectability is reasonably assured. The Company's sales policy is to require customers to provide purchase orders establishing selling prices and shipping terms. The Company evaluates the credit risk of each customer and establishes an allowance of doubtful accounts for any credit risk. Sales returns and allowances are estimated upon shipment.

Shipping and Handling Costs. Shipping and handling costs are included in cost of sales.

Trade Marketing and Merchandising. In order to support the Company's proprietary Nutraceutical product lines, various promotional activities are conducted through the retail trade, distributors or directly with consumers, including in-store display and product placement programs, feature price discounts, coupons, and other similar activities. The Company regularly reviews and revises, when it deems necessary, estimates of costs to the Company for these promotional programs based on estimates of what will be redeemed by the retail trade, distributors, or consumers. These estimates are made using various techniques, including historical data on performance of similar promotional programs. Differences between estimated expense and actual performance are generally not material and are recognized as a change in management's estimate in a subsequent period.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF MARCH 31, 2011 AND JUNE 30, 2010 AND FOR THE
THREE AND NINE MONTHS ENDED MARCH 31, 2011 AND 2010
(in thousands, except share and per share amounts)

Supplemental Statement of Cash Flows

Earnings Per Share. Basic earnings per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, warrants and convertible preferred stock, subject to anti-dilution limitations using the treasury stock method.

Note 2. Liquidity and Going Concern

The Company's condensed consolidated financial statements have been prepared assuming that it will continue as a going concern. The Company has incurred recurring operating losses and negative operating cash flows for four consecutive years including a net loss attributable to common stockholders of \$5,535 and negative operating cash flows of \$132 for the year ended June 30, 2010. For the nine months ended March 31, 2011, the Company had an operating loss of \$40, a net loss of \$1,300 and had operating cash flows from operations of \$373. As of March 31, 2011, the Company had cash of \$606 and a working capital deficit of \$10,643, which is primarily attributable to the amended Notes Payable (See Note 6(a)(ii)) in the amount of \$7,805, which matured on November 15, 2009, the Convertible Note Payable in the amount of \$4,500, which matured on February 21, 2011 (See Note 6(a)(i)) and an accumulated deficit of \$51,200. These factors raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result from this uncertainty.

The Company has defaulted on all of its outstanding debt instruments in the aggregate amount of \$12,605 by failing to repay them on their respective scheduled maturity dates. The Notes Payable are secured by a pledge of substantially all of the Company's assets. On March 19, 2010, the Company received a payment demand (the "Notice") for default interest (18% per annum) from one of the holders of the Notes Payable representing approximately 73% of the outstanding balance (the "Holder"). As of May 17, 2011, the Company has not repaid the Notes Payable or the default interest referenced in the Notice. However, the Company and the Holder continue to negotiate in good faith and the Company is actively working towards paying the Holder's Notes Payable, by, among other things, (i) selling certain assets of the Company, including the branded proprietary nutraceutical product line (see Note 3. Discontinued Operations) and the investment in iBio (ii) refinancing the Notes Payable and (iii) requiring a pledge by two of the most significant shareholders and directors of the Company, E. Gerald Kay and Carl DeSantis of additional collateral, as well as limited personal guarantees by them.

There can be no assurance that the Company will be able to repay, restructure or amend the Notes Payable or the Convertible Note Payable. In the interim, the Company has continued to make timely interest payments to the Note Payable holders at the non default rate of 8% per annum and is evaluating its strategic alternatives, which may include business divestitures, developing business and sales strategies to increase operating income, the sale of some or all of the Company's assets or operating subsidiaries and/or capital restructuring plans. In addition, if the Company is unsuccessful in finalizing the contemplated debt restructuring with respect to the Notes Payable with its current lenders and/or replacing its current lenders, its ability to continue as a going concern could be further impacted.

As of May 17, 2011, the Company has not received any additional demand payment notices for payment in full of the Company's obligations; however, the amended Note Holders continue to reserve their rights and remedies under the Securities Purchase Agreement and the related Notes Payable.

8

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF MARCH 31, 2011 AND JUNE 30, 2010 AND FOR THE
THREE AND NINE MONTHS ENDED MARCH 31, 2011 AND 2010
(in thousands, except share and per share amounts)

On February 21, 2011, the Convertible Note Payable became due and the Company defaulted on the payment. The Convertible Note Holder is also a significant shareholder and has not made any payment demands on the Company or converted the note into common shares of the Company.

If the Notes Payable and Convertible Note Payable are not restructured, and as a result of the events of default that arose based upon the Company's failure to pay each of the Notes Payable and Convertible Note Payable at maturity, the note holders have the right to give the Company an Acceleration Notice, under each of the Notes Payable and the Convertible Note Payable, which would (i) accelerate the payment of all unpaid principal and accrued and unpaid interest (including default interest (if any)) on the Notes Payable and the Convertible Note Payable, respectively, and (ii) require the Company to pay an amount equal to the sum of all of the respective amounts described in the preceding clause (i) in same day funds on the payment date specified in the notice, provided such date must be at least two (2) business days following the date on which the notice is delivered to the Company. If the Company is unable to raise additional capital, sell certain assets or successfully refinance the full outstanding amount of its Notes upon acceptable terms, it would have a material adverse effect on the Company, including the possible foreclosure by the note holders of the Company's assets.

Note 3. Discontinued Operations

In the three months ended March 31, 2011, as a result of the Company's negotiations with the Notes Payable holders, the Company determined that in order to repay the Notes Payable which matured on November 16, 2009 and are currently in default, and to effect the Company's strategic business plan to revert to its original core business of solid dosage manufacturing; the Company would seek to sell the net assets of AgroLabs in order to repay a portion of the defaulted balance of the Notes Payable from the proceeds of any sale. Accordingly, the Company classified the business assets and liabilities of its branded proprietary nutraceutical business and the results of operations as discontinued operations. As such, the operations of AgroLabs for the current and prior periods and the associated results of operations, financial position and cash flows are separately reported as discontinued operations for all periods presented.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF MARCH 31, 2011 AND JUNE 30, 2010 AND FOR THE
THREE AND NINE MONTHS ENDED MARCH 31, 2011 AND 2010
(in thousands, except share and per share amounts)

The net assets classified as discontinued operations were comprised of the following:

The Company's net sales, gross profit (loss) and results of operations classified as discontinued operations were as follows:

10

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF MARCH 31, 2011 AND JUNE 30, 2010 AND FOR THE
THREE AND NINE MONTHS ENDED MARCH 31, 2011 AND 2010
(in thousands, except share and per share amounts)

Note 4. Inventories

Inventories are stated at the lower of cost or market using the first-in, first-out method and consist of the following as of:

Note 5. Property and Equipment, net

Property and equipment consists of the following as of:

Depreciation and amortization expense was \$79 and \$76 for the three months ended March 31, 2011 and 2010, respectively and \$231 and \$206 for the nine months ended March 31, 2011 and 2010, respectively. In the nine months ended March 31, 2011, the Company disposed of fully depreciated machinery and equipment in the amount of \$137 for a gain of \$30. Included in the Company's income (loss) from discontinued operations is depreciation expense of \$7 and \$9 for the three months ended March 31, 2011 and 2010, respectively and \$29 and \$25 for the nine months ended March 31, 2011 and 2010, respectively.

Note 6. Notes Payable, Convertible Note Payable – CD Financial, LLC and Series C Redeemable Convertible Preferred Stock

(a) On February 21, 2008, the Company entered into two Securities Purchase Agreements (the "SPAs") relating to a private placement of securities with two investors, one of whom is an affiliate of Carl DeSantis, a director of the Company, which resulted in gross proceeds, in the aggregate, of \$17,337 to the Company. The private placement involved the sale of (i) 6,000 shares of newly designated Series C Redeemable Convertible Preferred Stock (the "Series C Preferred Stock") with a stated value of \$1,000 per share (all of the Series C Redeemable Convertible Preferred Stock was converted into the Company's common stock in July and August 2008), (ii) \$4,500 in principal amount of 9.5% Convertible Note Payable (the "Convertible Note Payable"), (iii) \$7,000 in principal amount of 8.0% Notes Payable (the "Notes Payable") and (iv) 200,000 shares of the Company's common stock. The Company also has recorded \$218 of deferred financing costs associated with the SPAs and \$130 of such deferred financing costs were netted against the gross proceeds received. These costs were allocated to each of the components of the transaction, based on the relative fair values and are amortized based on the terms of the component of the transaction to which the costs were allocated. The Notes Payable and the Convertible Note Payable are secured by a pledge of substantially all of the Company's assets. Concurrently with entry into the SPAs, the Company terminated its outstanding credit facilities with Amalgamated Bank in the amount of \$16,333 with the repayment of \$16,006.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF MARCH 31, 2011 AND JUNE 30, 2010 AND FOR THE
THREE AND NINE MONTHS ENDED MARCH 31, 2011 AND 2010
(in thousands, except share and per share amounts)

(i) CD Financial, LLC (“CD Financial”), a related party, provided gross proceeds of \$7,500, exclusive of a \$163 discount to be repaid by the Company at a future date (included in accrued expenses as of March 31, 2011 and June 30, 2010 in the accompanying Condensed Consolidated Balance Sheet), in exchange for 3,000 shares of Series C Preferred Stock, with a stated value of \$1,000 per share, and \$4,500 in principal amount of Convertible Note Payable. The Company allocated the proceeds and the discount based on the relative fair value of the Convertible Note Payable and the Series C Preferred Stock. The Company is amortizing to interest expense the discount applied to the Convertible Note Payable over the term of the note, and charged to Additional Paid in Capital the discount applied to the Series C Preferred Stock. As of March 31, 2011 and June 30, 2010, the unpaid discount on the Series C Preferred Stock and Convertible Note Payable in the amount of \$163 is included in accrued expenses in the accompanying Condensed Consolidated Balance Sheet.

As of July 1, 2009, the Company recorded an accumulated adjustment to account for the embedded derivative liability of the conversion feature of the Convertible Note Payable, resulting in a decrease to additional paid in capital of \$715, a decrease in accumulated deficit of \$2,097, a decrease in the carry value of the Convertible Note Payable of \$1,426 and the recognition of a derivative liability of \$44. As of March 31, 2011 and June 30, 2010, the related derivative liability to the Convertible Note Payable had no value.

The Company used the following assumptions to calculate the fair value of the derivative liability (assuming that 2,250,000 shares of common stock are converted) using the Black-Scholes option pricing model:

The Convertible Note Payable bears interest at an annual rate of 9.5% and matured on February 21, 2011. As of May 17, 2011, the Company is in default for the nonpayment of the Convertible Note Payable at maturity. The Convertible Note Payable may be converted, at any time and at the holder’s option, into shares of our common stock based on a conversion price as set out in the Convertible Note Payable. The conversion price is a formula that bases the conversion price on the greater of (i) 90% of the average Volume Weighted Average Price market price of our common stock for 20 trading days immediately preceding the conversion date and (ii) \$2.00, subject to adjustment in the event of a stock dividend, stock split or combination, reclassification or similar event and upon certain issuances below the conversion price.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF MARCH 31, 2011 AND JUNE 30, 2010 AND FOR THE
THREE AND NINE MONTHS ENDED MARCH 31, 2011 AND 2010
(in thousands, except share and per share amounts)

Included in Interest Expense in the accompanying Condensed Consolidated Statement of Operations, is the following accretion costs:

As of March 31, 2011, the Company had interest in arrears of \$217 on the Convertible Note Payable. In March 2009, the Company and CD Financial entered into an oral agreement to suspend the cash interest payments on the Convertible Note Payable until the Company returned to positive cash flows in its operations. In this oral agreement, CD Financial agreed not to give any default notices or increase interest rates due to such default (the default interest rate as defined in the Convertible Note Payable is 18%). The Company resumed interest payments on the Convertible Note Payable in August of 2009. In March 2010, CD Financial orally agreed to defer the interest owed for April 2010, in the amount of \$36, until the Company returned to positive cash flows to assist the Company in meeting its short term cash flow requirements. The Company has made timely monthly interest payments, beginning with the May 2010 monthly interest obligation.

Also, in accordance with the Convertible Note Payable, the Company will issue and deliver to CD Financial, for no additional consideration, 50,000 shares of common stock, on a quarterly basis in arrears, commencing with the three-month anniversary of the issuance date, until the Convertible Note Payable has been repaid in full, after which the Company's obligations to issue shares of common stock will no longer be applicable.

(ii) Imperium provided gross proceeds of \$9,837, including a discount of \$163, in exchange for 3,000 shares of Series C Preferred Stock, with a stated value of \$1,000 per share, \$7,000 in principal amount of 8.0% Notes Payable and 200,000 shares of the Company's common stock. The Notes Payable originally matured on February 21, 2009. The Company allocated the proceeds and the discount based on the relative fair value of the Notes Payable, the Series C Preferred Stock and the Company's common stock. The Company amortized, to interest expense, the discount applied to the Notes Payable over the term of the notes and charged to Additional Paid in Capital the discounts applied to the Series C Preferred Stock and the common stock. The Company recorded a beneficial conversion feature on the Series C Preferred Stock of \$608. The beneficial conversion feature was accreted over the five-year maturity period until the redemption of the Series C Preferred Stock in August 2008. The beneficial conversion features were accreted using the effective interest rate method.

On October 14, 2008, the Company and the Notes Payable holders amended their SPA to extend the maturity from February 21, 2009 to November 15, 2009 (See Note 2. Liquidity and Going Concern). In consideration for extending the maturity of the Notes Payable, the Notes Payable holders will forgo the 200,000 shares of common stock as additional interest and the Company (i) granted a 11.5% premium on the principal, thus aggregating a principal balance due of \$7,805 and certain other amounts payable under the Notes Payable, if any, (ii) certain new covenants are applicable to the Company effective October 14, 2009, (iii) the Company issued warrants to purchase 500,000 shares of the Company's Common Stock, with a five year term at an exercise price of \$0.80 per share, and (iv) the registration of the resale of the shares of the Company's Common Stock for which the warrants are exercisable.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF MARCH 31, 2011 AND JUNE 30, 2010 AND FOR THE
THREE AND NINE MONTHS ENDED MARCH 31, 2011 AND 2010
(in thousands, except share and per share amounts)

The amended Notes Payable in the amount of \$7,000 bear an interest rate of 8.0% and matured on November 15, 2009. The Company accreted the premium of \$805 over the term of the amendment, using the effective interest method, which resulted in additional interest expense for the three and six months ended December 31, 2009 of \$96 and \$288. As of July 1, 2009, the warrants issued were deemed to have a derivative liability resulting in an accumulated adjustment to account for the embedded derivative liability of the strike price resulting in a decrease to additional paid in capital of \$169, a decrease in accumulated deficit of \$140. As of March 31, 2011 and June 30, 2010, the related derivative liability with respect to the amended Notes Payable had estimated fair values of \$54 and \$18, which is included in accrued expenses and other current liabilities in the accompanying condensed balance sheets.

The Company used the following assumptions to calculate the fair value of the derivative liability using the Black-Scholes option pricing model:

The discount to the amended Notes Payable for the warrants which was accreted using the effective interest method resulted in interest expense for the three and nine months ended March 31, 2010 of none and \$65, respectively. There was no such expense recorded for the three and nine months ended March 31, 2011. The Company also recorded an additional \$10 of deferred financing costs as a result of the issuance of the amended Notes Payable.

On March 19, 2010, the Company received a payment demand (the "Notice") for default interest (18% per annum) from one of the holders of the Notes Payable representing approximately 73% of the outstanding balance of the Notes Payable (the "Holder"). As of May 17, 2011, the Company has not repaid the Notes Payable or the default interest on the Notes Payable. However, the Company and the Holder continue to negotiate in good faith and the Company is actively working towards repaying the Holder's Notes Payable, by, among other things, (i) selling certain assets of the Company, including the branded proprietary nutraceutical product line (see Note 3. Discontinued Operations) and the investment in iBio (ii) refinancing the Notes Payable and (iii) requiring a pledge by two of the most significant shareholders and directors of the Company, E. Gerald Kay and Carl DeSantis of additional collateral, as well as limited personal guarantees by them.

There can be no assurance that the Company will be able to repay, restructure or amend the Notes Payable. In the interim, the Company has continued to make timely interest payments to the Note Payable holders at the non-default rate of 8% per annum and to the Convertible Note Holder at the non-default rate of 9.5% per annum. As of May 17, 2011, the Company has not received any additional demand payment notices for payment in full of the Company's obligations; however, the amended Note Holders continue to reserve their rights and remedies under the Securities Purchase Agreement and the related Notes Payable. If the Notes Payable are not restructured, and as a result of the event of default that arose based upon the Company's failure to pay the Notes at maturity, the note holders have the right, to give the Company an Acceleration Notice, which would (i) accelerate the payment of all unpaid principal and accrued and unpaid interest (including default interest (if any)) on the Notes Payable, and (ii) require the Company to pay an amount equal to the sum of all of the amounts described in the preceding clause (i) in same day funds on the payment date specified in the notice, provided such date must be at least two (2) business days following the date on which the notice is delivered to the Company.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF MARCH 31, 2011 AND JUNE 30, 2010 AND FOR THE
THREE AND NINE MONTHS ENDED MARCH 31, 2011 AND 2010
(in thousands, except share and per share amounts)

(b) On November 24, 2009, Manhattan Drug, a wholly owned subsidiary of the Company, entered into a \$300 promissory note (the "CD Note") with CD Financial (see Note 6(a)(i)). The CD Note matured on November 24, 2010 and bears interest at the rate of 5%, which interest is payable quarterly. Interest is accrued monthly and is payable upon maturity. Interest in the amount of \$15, accrued for the period from the issuance date, November 24, 2009, through November 30, 2010, was paid in December 2010. As of March 31, 2011, the Company is in default under the CD Note as a result of the Company's failure to repay the CD Note on its scheduled maturity date. The CD Note is expected to remain outstanding until the Company satisfies the Company's obligations under the amended Notes Payable, (see Note 6(a)(ii)).

(c) On July 29, 2010, Manhattan Drug, a wholly owned subsidiary of the Company, entered into a second promissory note in the amount of \$40 (the "CD \$40 Note") with CD Financial (see Note 6(a)(i)). The CD \$40 Note matured on October 29, 2010 and bore interest at the rate of 5%. Manhattan Drug repaid the CD \$40 Note on October 29, 2010. Interest was accrued monthly and was paid on maturity.

The following table presents the stated value/principal of each of the securities issued in connection with the debt outstanding as of March 31, 2011:

The weighted average interest rate paid was 8.59% in each of the three and nine months ended March 31, 2011 and 2009. As of March 31, 2011 and June 30, 2010, the Company had accrued and unpaid interest of approximately \$302 and \$300, respectively, for the Notes Payable and Convertible Note Payable. (See Note 6(a) above).

Note 7. Significant Risks and Uncertainties

(a) Concentrations of Credit Risk-Cash. The Company maintains balances at several financial institutions. Deposits at each institution are insured by the Federal Deposit Insurance Corporation up to \$250. As of March 31, 2011, the Company had \$116 of uninsured deposits at these financial institutions.

(b) Concentrations of Credit Risk-Receivables. The Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk of its customers, establishes an allowance for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowances is limited. The Company does not require collateral in relation to its trade accounts receivable credit risk.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF MARCH 31, 2011 AND JUNE 30, 2010 AND FOR THE
THREE AND NINE MONTHS ENDED MARCH 31, 2011 AND 2010
(in thousands, except share and per share amounts)

(c) Major Customers. For the three and nine months ended March 31, 2011, approximately 86.0% and 87.4%, respectively, of net sales were derived from two customers. For the three and nine months ended March 31, 2010, approximately 69.7% of revenues were derived from one customer and 78.6% of revenues was derived from two customers, respectively. Accounts receivable as of March 31, 2011 from the Company's two major customers represented approximately 63% of total net accounts receivable. The loss of these customers would have an adverse affect on the Company's operations. Major customers are those customers who account for more than 10% of net sales.

(d) Other Business Risks. The Company insures its business and assets against insurable risks, to the extent that it deems appropriate, based upon an analysis of the relative risks and costs. The Company believes that the risk of loss from non-insurable events would not have a material adverse effect on the Company's operations as a whole.

The raw materials used by the Company are primarily commodities and agricultural-based products. Raw materials used by the Company in the manufacture of its nutraceutical products are purchased from independent suppliers. Raw materials are available from numerous sources and the Company believes that it will continue to obtain adequate supplies.

Approximately 54% the Company's employees, located in its New Jersey facility, are covered by a union contract. The contract was renewed in August 2010 and will expire in August 2011.

Note 8. Commitments and Contingencies

(a) Leases

Related Party Leases. Warehouse and office facilities are leased from Vitamin Realty Associates, L.L.C., a limited liability company, which is 90% owned by the Chairman of the Company's Board of Directors, a director and majority shareholder and certain of his family members and 10% owned by an employee of the Company. The lease provides for minimum annual rental payment of \$324 through May 31, 2015 plus increases in real estate taxes and building operating expenses. On July 1, 2004, the Company leased an additional 24,810 square feet of warehouse space on a month-to-month basis.

Rent expense for the three and nine months ended March 31, 2011 and 2010 on these leases were \$202 and \$195 and \$570 and \$560, respectively, and are included in cost of sales in the accompanying Condensed Consolidated Statements of Operations. As of March 31, 2011 and June 30, 2010, the Company had an outstanding obligation of \$761 and \$686, respectively, included in accounts payable in the accompanying Condensed Consolidated Balance Sheet.

Other Lease Commitments. The Company has entered into certain non-cancelable operating lease agreements expiring up through May 31, 2015, related to office and warehouse space, equipment and vehicles. Total rent expense, including real estate taxes and maintenance charges, was approximately \$294 and \$286 for the three months ended March 31, 2011 and 2010, respectively, and \$851 and \$817 for the nine months ended March 31, 2011 and 2010, respectively. Rent expense is included in cost of sales, selling and administrative expenses and income (loss) from discontinued operations in the accompanying Condensed Consolidated Statements of Operations. Rent expense included in income (loss) from discontinued operations was approximately \$60 and \$62 for the three months ended

March 31, 2011 and 2010, respectively, and \$181 and \$182 for the nine months ended March 31, 2011 and 2010, respectively.

16

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF MARCH 31, 2011 AND JUNE 30, 2010 AND FOR THE
THREE AND NINE MONTHS ENDED MARCH 31, 2011 AND 2010
(in thousands, except share and per share amounts)

The minimum rental commitment for long-term non-cancelable leases from continuing operations is as follows:

(b) Consulting Agreements.

Effective July 1, 2008, the Company entered into a consulting agreement with Jeffrey Leach (an employee of the Company as of the date of the agreement and its former President and Chief Executive Officer). Pursuant to the consulting agreement, Mr. Leach is to provide consulting and specialized services to the Company in the area of finance, acquisition of product lines, refinancing of existing debt and capital raising under the direction of the Company, including for any company in which the Company has an ownership interest. In connection with the agreement, the Company issued 250,000 shares of the Company's common stock to Mr. Leach, the remaining 83,333 shares vested in January 2011 (See Note 10. Equity Transactions).

(c) Legal Proceedings.

The Company is subject, from time to time, to claims by third parties under various legal theories. The defense of such claims, or any adverse outcome of any such claims, could have a material adverse effect on the Company's liquidity, financial condition and cash flows. As of May 17, 2011, management believes that there are no significant legal matters pending that would have a material effect on the Company's liquidity, financial condition or cash flows.

Note 9. Related Party Transactions

CD Financial has guaranteed certain liabilities of the Company. On April 7, 2009, CD Financial entered into a Guaranty Agreement with Creative Flavors, Inc. ("CFC"), a major supplier of the Company, guaranteeing up to \$500 of the Company's outstanding obligations to CFC. The guaranty was terminated on March 10, 2010 by written notice to CFC from CD Financial. As of June 30, 2010, the Company had an outstanding obligation to CFC in the amount of \$151 under the guarantee, which amount is included in accounts payable in the Company's Consolidated Balance Sheet. The Company paid this liability in August 2010.

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF MARCH 31, 2011 AND JUNE 30, 2010 AND FOR THE
THREE AND NINE MONTHS ENDED MARCH 31, 2011 AND 2010
(in thousands, except share and per share amounts)

CD Financial has not received any compensation from the Company in connection with this guarantee.

The Company has a verbal consulting agreement with Eugene Kay, a former employee of the Company and a brother of E. Gerald Kay, the Company's Chief Executive Officer, Chairman of the Board, President, and majority shareholder. This agreement is on a month-to-month basis and provides for payment by the Company of a fee in the amount of approximately \$1.3 per month. The total consulting expense recorded in connection with this verbal agreement was approximately \$4 and \$12 in each of the three and nine months ended March 31, 2011 and 2010, respectively.

See Note 6(a)(i) and 6(b)(c) – Notes Payable and Convertible Note Payable – CD Financial, LLC for related party securities transactions.

See Note 8(a) - Leases for related party lease transactions.

Note 10. Equity Transactions

(a) Stock Option Plan and Warrants. There were no stock options or warrants issued in the three and nine months ended March 31, 2011 and 2010. During the three and nine months ended March 31, 2011 and 2010, the Company has incurred stock compensation expense of \$12 and \$159 and \$227 and \$704, respectively. Stock compensation included in income (loss) from discontinued operations in the three and nine months ended March 31, 2011 and 2010, was \$3 and \$10 and \$19 and \$24, respectively.

During the three and nine months periods ended March 31, 2011 and 2010, total options and warrants to purchase shares of common stock of 3,274,255 and 3,249,255, respectively, were outstanding but were not included in the computation of diluted earnings per share as they were anti-dilutive as a result of net losses applicable to common shareholders during the periods.

During each of the three and nine months ended March 31, 2011 and 2010, options to purchase 480,834 and 25,000 shares of common stock, respectively, with exercise prices below the market price were outstanding but were not included in the computation of diluted earnings per share as they are anti-dilutive as a result of net losses during the period.

For both the three and nine months ended March 31, 2011 and 2010, common share equivalents of 2,250,000 related to the Convertible Note Payable were not included in the computation of diluted earnings per share as they were anti-dilutive as a result of net losses.

(b) Consulting Agreement. Effective July 1, 2008, the Company entered into a three-year consulting agreement which resulted in the issuance of 250,000 shares of the Company's common stock. On the effective date of the consulting agreement, the Company recognized prepaid consulting expenses of \$593 with a corresponding increase in common stock and additional paid in capital. During each of the three and nine months ended March 31, 2011 and 2010, the Company amortized \$49 and \$147, respectively, to selling and administrative expenses in the Company's Condensed Consolidated Statement of Operations. The remaining consulting expense of \$50 will be amortized into selling and administrative expenses over the remaining three month term of the consulting agreement.

Note 11. Income Taxes

The Company recognizes deferred tax assets, net of applicable valuation allowances, related to net operating loss carry-forwards and certain temporary differences and deferred tax liabilities related to certain temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting. The Company recognizes a future tax benefit to the extent that realization of such benefit is considered to be more likely than not. This determination is based on projected taxable income and tax planning strategies. Otherwise, a valuation allowance is applied.

18

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

Certain statements set forth under this caption constitute "forward-looking statements." See "Disclosure Regarding Forward-Looking Statements" on page 1 of this Report for additional factors relating to such statements. The following discussion should also be read in conjunction with the condensed consolidated financial statements of the Company and Notes thereto included elsewhere herein and the Company's Annual Report on Form 10-K.

The Company is engaged primarily in the manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company's customers are located primarily throughout North America.

Business Outlook

Our future results of operations and the other forward-looking statements contained in this Form 10-Q, including this MD&A, involve a number of risks and uncertainties—in particular, the statements regarding our goals and strategies, new product introductions, plans to cultivate new businesses, pending divestitures, future economic conditions, revenue, pricing, gross margin and costs, the tax rate, and potential legal proceedings. We continue to focus our efforts on improving operational efficiency and reducing spending that may have an impact on expense levels and gross margin and diversifying our customer base. In addition to the various important factors discussed above, a number of other important factors could cause actual results to differ significantly from our expectations. See the risks described in "Risk Factors" in Part II, Item 1A of this Form 10-Q.

In the three months ended March 31, 2011, as a result of the Company's negotiations with the Notes Payable holders, the Company determined that in order to repay the Notes Payable which matured on November 16, 2009 and are currently in default, and to effect the Company's strategic business plan to revert to its original core business of solid dosage manufacturing; the Company would seek to sell the net assets of AgroLabs in order to repay a portion of the defaulted balance of the Notes Payable from the proceeds of any sale. Accordingly, the Company classified the business assets and liabilities of its branded proprietary nutraceutical business and the results of operations as discontinued operations. As such, the operations of AgroLabs for the current and prior periods and the associated results of operations, financial position and cash flows are separately reported as discontinued operations for all periods presented.

Our financial results are substantially dependent on net sales. Net sales are partly a function of the mix of contract manufactured products and other nutraceutical sales which are difficult to forecast. The branded proprietary net sales are included in income (loss) from discontinued operations and continue to influence our financial results. The varied sales pricing among our products and promotional support in the form of consumer coupons or other sales price allowances, along with the mix of products sold affects the average selling price that we will realize and has a large impact on our revenue and gross margins. Net sales in our operations of AgroLabs, classified as discontinued operations, is also affected by the timing of new product introductions and the demand for and market acceptance of our products; actions taken by our competitors, including new product offerings and introductions, marketing programs and pricing pressures, and our response to such actions; our ability to respond quickly to consumer tastes and needs; and the availability of sufficient raw materials and production lead-time from suppliers to meet demand. Factors that could cause demand to be different from our expectations include customer acceptance of our products and our competitors products; changes in customer order patterns, including order returns; changes in the level of inventory at customers; and changes in business and economic conditions, including conditions in the credit market that could affect consumer confidence and result in lower than expected demand for our products.

We believe that we have the product offerings and introductions, facilities, personnel, and competitive and financial resources in place for business success; however, future revenue, costs, gross margins, and profits are all influenced

by a number of factors, including those discussed above, all of which are inherently difficult to forecast.

Critical Accounting Policies and Estimates

There have been no changes to our critical accounting policies in the nine months ended March 31, 2011. Critical accounting policies and the significant estimates made in accordance with them are regularly discussed with our Audit Committee. Those policies are discussed under “Critical Accounting Policies” in our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Item 7 of our Annual Report on Form 10-K for the year ended June 30, 2010.

Results of Operations

Our results from operations in the following table sets forth the income statement data of our results as a percentage of net sales for the periods indicated:

For the nine months ended March 31, 2011 compared to the nine months ended March 31, 2010

Sales, net. Sales, net, for the nine months ended March 31, 2011 and 2010 were \$18.4 million and \$14.2 million, respectively, an increase of approximately \$4.2 million or 29.8%. The increase is comprised of the following:

For the nine months ended March 31, 2011, approximately 87% of total net sales were derived from two customers as compared to 79% of total net sales for the nine months ended March 31, 2010. The loss of either of these two customers would have an adverse affect on our operations.

The increase in our net sales is primarily the result of an increase of approximately \$4.5 million in our contract manufacturing product sales from increased sales to one of our major customers, Herbalife, including the substantial increase in international sales of approximately \$2.7 million. This increase was offset by a decrease in our other nutraceutical product lines in net sales decreases of approximately \$0.3 million compared to the prior period.

Cost of sales. Cost of sales increased by \$2.9 million to \$15.8 million for the nine months ended March 31, 2011 as compared to \$12.8 million for the nine months ended March 31, 2010. Cost of sales decreased as a percentage of sales to 85.7% for the nine months ended March 31, 2011 as compared to 90.5% for the nine months ended March 31, 2010. The increase in cost of goods sold amount was primarily the result of increased sales. The cost of sales as a percentage of sales decreased as we benefited from spreading the fixed manufacturing costs over an increased amount of products manufactured and sold to our customers.

Selling and Administrative Expenses. Selling and administrative expenses were \$2.7 million for the nine months ended March 31, 2011, as compared to \$3.2 million for the nine months ended March 31, 2010, a decrease of \$0.5 million or 16.8%. As a percentage of sales, net, selling and administrative expenses were 14.5% for the nine months ended March 31, 2011 and 22.7% for the prior comparable period.

The net decrease in selling and administrative expenses of \$0.5 million is mainly due to increases (decreases) in:

- compensation and employee benefits - (\$0.2 million),
- stock compensation expenses - (\$0.5 million), and
- professional fees - \$0.1 million;

Our compensation and employee benefits decreased by \$0.2 million as a result of decreasing our corporate staff by two employees, the suspension of the Company's matching of employees' retirement savings deferrals in the profit sharing plan and the decreased cost resulting from switching professional employment organizations, which reduced administrative costs with outsourcing our human resources functions and employee benefits.

Our stock compensation expense decreased by \$0.5 million primarily due to the significant decrease in the market value of our common stock at the measurement date of the stock option grants (the market value of our common stock is one of several factors used in determining the fair value of the stock compensation at the time of the award and ultimate expense to our consolidated financial statements) and due to the lack of any stock options being granted in the fiscal year ended June 30, 2010 and the nine months ended March 31, 2011.

Our professional fees increased by \$0.1 million primarily due to increased legal costs incurred in negotiating with our Notes Payable holders and increased consulting fees in connection with our strategic planning initiatives.

Other expense, net. Other expense, net was approximately \$1.4 million for the nine months ended March 31, 2011 compared to \$1.5 million for the nine months ended March 31, 2010, a decrease of \$0.1 million. Interest expense represents approximately \$1.4 million of other expense in the nine months ended March 31, 2011 compared to \$1.6 million in the nine months ended March 31, 2010, a decrease of \$0.2 million. The decrease in interest expense is attributable to lower accretion in the nine months ended March 31, 2011 compared to the nine months ended March 31, 2010. This decrease was offset by an increase of approximately \$0.1 million in the change in fair market value of derivative liabilities from a benefit of \$50,000 in the nine months ended March 31, 2010 to an increased expense of \$36,000 in the nine months ended March 31, 2011, primarily due to an increase in the closing trading price of our common stock on the fair value measurement date, one of the factors used in determining the fair value of derivative liabilities.

Federal and state income tax, net. For the nine months ended March 31, 2011 and March 31, 2010, we had a small amount of state tax expenses. We continue to provide a full reserve on our deferred tax assets as it has been determined that based upon past losses, the Company's liquidity concerns, and the current economic environment, that it is "more likely than not" that the Company's deferred tax assets may not be realized.

Loss from discontinued operations. In the three month period ended March 31, 2011, we determined that in order to repay the Notes Payable, which matured on November 16, 2009, and to affect our strategic business plan to revert to our original core business of solid dosage manufacturing, we would seek to sell the net assets of AgroLabs. The net income from the operations of AgroLabs (classified as discontinued operations), included in our results for the nine months ended March 31, 2011, was \$0.1 million compared to a net loss of \$0.5 million in the nine months ended March 31, 2010. The change of \$0.6 million from a net loss to net income in AgroLabs was primarily the result of increased operating income of \$1.0 million (resulting from improved gross margins on lower sales (\$0.4 million) and decreased selling and administrative costs (\$0.6 million, primarily from decreases in advertising and professional fees)) offset by the lack of any gains from legal settlements in the nine months ended March 31, 2011, compared to receiving net settlements of \$0.4 million in the nine months ended March 31, 2010.

Net loss. Our net loss for the nine months ended March 31, 2011 was \$1.3 million as compared to \$3.9 million for the nine months ended March 31, 2010. This decrease in net loss of approximately \$2.6 million is primarily the result of the decrease in operating losses from continuing operations of \$2.0 million and the increase to net income from discontinued operations of approximately \$0.6 million.

For the three months ended March 31, 2011 compared to the three months ended March 31, 2010

Sales, net. Sales, net, for the three months ended March 31, 2011 and 2010 were \$6.3 million and \$5.3 million, respectively, an increase of approximately \$1.0 million or 18.1%. The increase is comprised of the following:

For the three months ended March 31, 2011, approximately 86% of total net sales were derived from two customers as compared to 70% of total net sales from one customer for the three months ended March 31, 2010. The loss of either of these two customers would have an adverse affect on our operations.

The increase in our net sales is the result of increased sales in our contract manufacturing business of approximately \$1.0 million, which included an increase of approximately \$1.2 million of increased international sales to our major customer, Herbalife, offset by a decrease of approximately \$0.2 million from other international customers. The performance of our remaining Nutraceutical product lines were substantially the same in each of the three month periods ended March 31, 2011 and 2010.

Cost of sales. Cost of sales increased by \$0.6 million to \$5.4 million for the three months ended March 31, 2011 as compared to \$4.8 million for the three months ended March 31, 2010. Cost of sales decreased as a percentage of sales to 86.2% for the three months ended March 31, 2011 as compared to 89.7% for the three months ended March 31, 2010. The increase in cost of goods sold amount was primarily the result of increased sales. The cost of sales as a percentage of sales decreased as we benefited from spreading the fixed manufacturing costs over an increased amount of products manufactured and sold to our customers.

Selling and Administrative Expenses. Selling and administrative expenses were \$0.8 million for the three months ended March 31, 2011, as compared to \$1.0 million for the three months ended March 31, 2010, a decrease of \$0.2 million or approximately 14.5%. As a percentage of sales, net, selling and administrative expenses were 13.3% for the three months ended March 31, 2011 and 18.4% for the prior comparable period.

The net decrease in selling and administrative expenses of \$0.2 million is mainly due to a decrease in stock compensation of \$0.2 million. Stock compensation decreased by \$0.2 million primarily due to the significant decrease in the market value of our common stock at the measurement date of the stock option grants (the market value of our common stock is one of several factors used in determining the fair value of the stock compensation at the time of the award and ultimate expense to our consolidated financial statements) and due to the lack of any stock options being granted in the fiscal year ended June 30, 2010 and the three months ended March 31, 2011.

Other expense, net. Other expense, net was approximately \$0.4 million for each of the three months ended March 31, 2011 and 2010. Interest expense represents substantially all of other expense, net in each of the three months ended March 31, 2011 and 2010.

Federal and state income tax, net. For the three months ended March 31, 2011 and March 31, 2010, we had a small amount of state tax expenses. We continue to provide a full reserve on our deferred tax assets as it has been determined that based upon past losses, the Company's liquidity concerns, and the current economic environment, that it is "more likely than not" that the Company's deferred tax assets may not be realized.

Loss from discontinued operations. In the three month period ended March 31, 2011, we determined that in order to repay the Notes Payable, which matured on November 16, 2009, and to affect our strategic business plan to revert to our original core business of solid dosage manufacturing, we would seek to sell the net assets of AgroLabs. The net loss from AgroLabs, included in our results for the three months ended March 31, 2011 was \$0.5 million compared to approximately \$1.1 million in the three months ended March 31, 2010. The decrease in net loss from discontinued operations of \$0.6 million was primarily the result of increased operating income of \$1.0 million (resulting from improved gross margins on lower sales (\$1.3 million), offset by increased selling and administrative costs (\$0.2 million, primarily from increased advertising costs)) and the lack of any gains from legal settlements in the three months ended March 31, 2011 compared to receiving a settlements of \$0.5 million in the three months ended March 31, 2010.

Net loss. Our net loss for the three months ended March 31, 2011 was \$0.9 million as compared to \$1.9 million for the three months ended March 31, 2010. This decrease in net loss of approximately \$1.04 million is the result of the decreases in the operating losses from continuing operations of \$0.46 million and the decrease in the loss from discontinued operations of approximately \$0.58 million.

Seasonality

The Nutraceutical business tends to be seasonal. We have found that in our second fiscal quarter ending on December 31st of each year, orders from our significant customers decrease for our manufacturing services of solid dosage nutraceutical products.

The Company believes that there are other non-seasonal factors that also may also influence the variability of quarterly results including, but not limited to, general economic and industry conditions that affect consumer spending, changing consumer demands and current news on nutritional supplements. In addition, our recent growth has caused additional variability in our quarterly results. Accordingly, a comparison of the Company's results of operations from consecutive periods is not necessarily meaningful, and the Company's results of operations for any period are not necessarily indicative of future periods.

Liquidity and Capital Resources

The following table sets forth, for the periods indicated, the Company's net cash flows used in operating, investing and financing activities, its period end cash and other operating measures:

At March 31, 2011, our working capital deficit was approximately \$10.6 million, an increase of approximately \$0.9 million from the working capital deficit of approximately \$9.7 million at June 30, 2010. Our current assets decreased by \$0.5 million and our current liabilities increased by \$0.4 million from June 30, 2010 to March 31, 2011. The primary increase in the working capital deficit was the result of accretion expense (a non cash expense) of \$0.9 million on the Convertible Note Payable from \$3.6 million at June 30, 2010 to the maturity value of \$4.5 million at March 31, 2011.

Net cash provided by operating activities of \$0.4 million in the nine months ended March 31, 2011, includes a net loss of \$1.3 million. After excluding the effects of non-cash expenses, including, depreciation and amortization, compensation expense for employee stock options and consultants and changes in the fair value of derivative liabilities, and the income from discontinued operations, the adjusted cash used in operations before the effect of the changes in working capital components was \$0.2 million. Cash in the amount of approximately \$0.3 million was used in continuing operations from our working capital assets and liabilities, and was the result of an increase in inventory of \$0.5 million, offset by increases in accounts receivable of approximately \$0.1 million and decreases in accounts payable and accrued expenses and other liabilities aggregating approximately \$0.7 million. Net cash of \$1.0 million was provided from operating activities from our discontinued operations.

Net cash used in operating activities of less than \$0.1 million in the nine months ended March 31, 2010, includes a net loss of \$3.9 million. After excluding the effects of non-cash expenses, including, depreciation and amortization, compensation expense for employee stock options and consultants and changes in the fair value of derivative liabilities, and the loss from discontinued operations, the adjusted cash used in operations before the effect of the changes in working capital components was \$1.6 million. Cash was used by continuing operations from our working capital assets and liabilities in the amount of approximately \$0.5 million, was the result of a decrease in accounts receivable of \$0.2 million and increases in accounts payable, accrued expenses and other liabilities of \$0.4 million, offset by an increase in inventory of \$1.0 million and prepaid expenses and other assets of \$0.1 million. Net cash of \$2.0 million was provided from operating activities from our discontinued operations.

Cash used in investing activities was used for the purchase of fixed assets for approximately \$245,000, offset by a gain on the sale of machinery and equipment of \$30,000 in the nine months ended March 31, 2011, compared to using approximately \$70,000 in the nine months ended March 31, 2010 for the purchase of machinery and equipment.

Cash used in financing activities was \$74,000 in the nine months ended March 31, 2011, which included a \$40,000 repayment of funds borrowed in the same nine months period under a short term promissory note entered into with CD Financial, a related party and the holder of our Convertible Note Payable, and the repayment of \$34,000 under our capitalized lease obligations. Cash provided by financing activities was \$0.3 million in the nine months ended March 31, 2010 and was provided by financing under a short term promissory note entered into with CD Financial, a related party and the holder of our Convertible Note Payable. We also used \$14,000 for repayments under our capitalized lease obligations during the nine months ended March 31, 2010.

Our condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. We have incurred recurring operating losses and negative operating cash flows for four consecutive fiscal operating years including a net loss attributable to common stockholders of \$5.5 million and negative operating cash flows of approximately \$132,000 for the fiscal year ended June 30, 2010. For the nine months ended March 31, 2011, we had a net operating loss of approximately \$40,000 and a net loss from continuing operations of approximately \$1.7 million. At March 31, 2011, we had cash of \$0.6 million, a working capital deficit of \$10.6 million, primarily attributable to the amended Notes Payable in the amount of \$7.8 million, which were due on November 15, 2009, the Convertible Note Payable in the amount of \$4.5 million, which was due on February 21, 2011 and an accumulated deficit of \$51.2 million. These factors raise substantial doubt as to our ability to continue as a going concern.

We have defaulted on all of our outstanding debt instruments in the aggregate amount of \$12.6 million by failing to repay them on their respective scheduled maturity dates. The Notes Payable and the Convertible Note Payable are secured by a pledge of substantially all of the Company's assets. On March 19, 2010, we received a payment demand (the "Notice") for default interest (18% per annum) from one of the holders of the Notes Payable representing approximately 73% of the outstanding balance (the "Holder"). As of May 17, 2011, we have not repaid the Notes Payable or the default interest referenced in the Notice. However, the Company and the Holder continue to negotiate

in good faith and we are actively working towards paying the Holder's Notes Payable, by, among other things, (i) selling certain of our assets, including the branded proprietary nutraceutical product line (see Note 3. Discontinued Operations) and the investment in iBio, (ii) refinancing the Notes Payable and (iii) requiring a pledge by two of the most significant shareholders and directors of the Company, E. Gerald Kay and Carl DeSantis of additional collateral, as well as, limited personal guarantees by them.

On February 21, 2011, the Convertible Note Payable became due and we defaulted on the payment. The Convertible Note Holder is also a significant shareholder and has not made any payment demands on us or converted the note into common shares of the Company.

There can be no assurance that we will be able to repay, restructure or amend the Notes Payable or the Convertible Note Payable. In the interim, we have continued to make timely interest payments to the Note Payable holders at the non-default rate of 8% per annum and to the Convertible Note Payable holder at the non-default rate of 9.5% per annum. As of May 17, 2011, we have not received any additional demand payment notices for payment in full of our obligations; however, the amended Note Holders continue to reserve their rights and remedies under the Securities Purchase Agreement and the related Notes Payable.

If the Notes Payable and the Convertible Note Payable are not restructured and as a result of the events of default that arose based upon our failure to pay each of the Notes Payable and Convertible Note Payable at maturity, the note holders have the right, to give us an Acceleration Notice, which would (i) accelerate the payment of all unpaid principal and accrued and unpaid interest (including default interest (if any)) on the Notes Payable and the Convertible Note Payable, respectively, and (ii) require us to pay an amount equal to the sum of all of the respective amounts described in the preceding clause (i) in same day funds on the payment date specified in the notice, provided such date must be at least two (2) business days following the date on which the notice is delivered to us. If we are unable to raise additional capital, sell certain assets or successfully refinance the full outstanding amount of the Notes Payable and the Convertible Note Payable upon acceptable terms, it would have a material adverse effect on us, including the possible foreclosure by the note holders of our assets.

Assuming the Company is able to raise additional capital and/or refinance its Notes Payable, and it is not adversely affected by the current economic conditions, we believe that our available capital as of March 31, 2011 will enable the Company to continue as a going concern. However, there can be no assurance that we will be able raise additional capital or finalize the restructuring or make payments through either the sale of certain of our assets or refinancing of the amended Notes Payable, nor that the current economic conditions will not negatively impact us. Furthermore, we are considering other strategic alternatives, which may include business divestitures, developing business and sales strategies to increase operating income, the sale of some or all of our assets or operating subsidiaries and/or capital restructuring plans. In addition, if we are unsuccessful in finalizing the contemplated debt restructuring with respect to the Notes Payable with our current lenders and/or replacing our current lenders, our ability to continue as a going concern could be further impacted. If we are unable to implement any strategic alternative, including raising additional capital or finalizing the restructuring of the full outstanding amount of our amended Notes Payable upon acceptable terms, it would have a material adverse effect on the Company, including possible foreclosure by the note holders of our assets.

Our total annual commitments, from continuing operations, at March 31, 2011 for long term non-cancelable leases of approximately \$0.4 million, consists of obligations under operating leases for facilities and lease agreements for the rental of warehouse equipment, office equipment and automobiles.

Capital Expenditures

The Company's capital expenditures for the nine months ended March 31, 2011 and 2010 were approximately \$0.2 million and less than \$0.1 million, respectively. The Company has budgeted approximately \$0.3 million for capital expenditures for fiscal 2011. The total amount is expected to be funded from cash provided from its operations and from lease financing.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Recent Accounting Pronouncement

Please refer to Note 1 to our condensed financial statements which can be found at page 6, herein.

Impact of Inflation

The Company does not believe that inflation has significantly affected its results of operations.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

Item 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Securities Exchange Act of 1934, as amended (the "Exchange Act") is recorded, processed, summarized, and reported within the time periods specified by the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, the Company has evaluated the effectiveness of its disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2011, and, based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these controls and procedures are effective in providing reasonable assurance of compliance.

Changes in Internal Control over Financial Reporting

No change in our internal control over financial reporting occurred during the three and nine months ended March 31, 2011 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

26

PART II – OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

None.

Item 1A. RISK FACTORS

The risks described in Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended June 30, 2010, could materially and adversely affect our business, financial condition and results of operations. The risk factors discussed in that Form 10-K do not identify all risks that we face because our business operations could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations. There have been no material changes to our risk factors from those disclosed in our Form 10-K for the year ended June 30, 2010.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Effective February 21, 2011, the Company issued 50,000 shares of common stock to CD Financial. See Note 6(a)(i) to the Condensed Consolidated Financial Statements – Notes Payable, Convertible Note Payable – CD Financial, LLC and Series C Redeemable Convertible Preferred Stock.

Item 3. DEFAULTS UPON SENIOR SECURITIES

The Company is in default with respect to \$7.8 million outstanding amount of Notes Payable as a result of the Company failing to repay the Notes Payable on their scheduled maturity date. See Note 6(a)(ii) to the Condensed Consolidated Financial Statements – Notes Payable, Convertible Note Payable – CD Financial, LLC and Series C Redeemable Convertible Preferred Stock.

Item 5. OTHER INFORMATION

None.

Item 6. EXHIBITS

(a) Exhibits

Exhibit
Number

- 31.1 Certification of pursuant to Section 302 of Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.
- 31.2 Certification of pursuant to Section 302 of Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.
- 32.1 Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.
- 32.2 Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INTEGRATED BIOPHARMA, INC.

Date: May 17, 2011

By: /s/ E. Gerald Kay
E. Gerald Kay,
President and Chief Executive Officer

Date: May 17, 2011

By: /s/ Dina L. Masi
Dina L. Masi,
Chief Financial Officer & Senior Vice President